ArticleBioactive materials2025
Evaluation of FeMnN alloy bioresorbable flow diverting stents in the rabbit abdominal aorta.
Article in Bioactive materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Defining biomaterial-driven design principles for bioabsorbable flow diverters: current state and perspectives.Bioactive materials · 2027Review
- Mechanical Properties and Corrosion Behavior of Biodegradable Metals: Current Challenges.Materials (Basel, Switzerland) · 2026Review
- Design of novel interlocked bi-layer NiTi braided stent with ultra-thin walls for urinary tract obstruction treatment.Regenerative biomaterials · 2026Article
- Zn ion-implanted absorbable Fe for improved cytocompatibility and mitigated neointimal hyperplasia.Regenerative biomaterials · 2026Article
- Educational Impact of a 3D Canine Vascular Simulator for Learning Anatomy and Interventional Radiology Techniques in Veterinary Training.Veterinary sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Flow diverting stents are braided, metallic endoluminal devices widely used to treat intracranial aneurysms. Bioresorbable flow diverters (BRFDs) are gaining traction as the next generation of flow diverter technology. BRFDs aim to occlude and heal the aneurysm before safely dissolving into the body, mitigating or eliminating complications associated with the permanent presence of conventional flow diverters such as thromboembolism and stenosis. Additional putative advantages of a BRFD include a reduction in metal induced medical imaging artifacts, a restoration of physiological vasoreactivity, and allowing physicians to re-access the aneurysm if an additional procedure is required. In this current study, iron-manganese-nitrogen (FeMnN) alloy BRFDs and permanent control FDs composed of an industry standard Cobalt-Nickel-Chromium alloy were deployed in the rabbit aorta. MicroCT and SEM corrosion analysis determined the FeMnN wire volumes and cross-sectional areas had reduced approximately 85 % and 95 % after 3- and 6-months implantation duration, respectively. Histological analysis demonstrated the BRFDs exhibited suitable biocompatibility, with no cases of in-stent thrombosis, clinically significant stenosis, or adverse tissue responses observed. Immunohistochemistry revealed the neointimas surrounding the BRFDs featured a confluent endothelium covering several layers of smooth muscle cells, with macrophages adjacent to the device wires. The macrophages were able to penetrate the corrosion product and were observed transporting corrosion products away from the implant site. This current work provides primary
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.